Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Dificid (fidaxomicin by Year
Dificid (fidaxomicin — C. difficile infection) — International sales ($M) ($M)
Merck Dificid (fidaxomicin: $45M in FY2025, up 21.6% from a year earlier.
Where the FY2025 figure comes from
“|| Dificid | 247 | 340 | -27 | 202 | 303 | -33 | 45 | 37 | 20”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Dificid (fidaxomicin — C. difficile infection) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45 | +21.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 37 | +32.1% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 28 | +27.3% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 22 | +120.0% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 10 | +42.9% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 7 | – | Form 10-K (filed 2023-02-24) ↗ |
Breakdown
What makes up dificid (fidaxomicin
Cite this data
StockData. (2026). Merck Dificid (fidaxomicin ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-dificid-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.